Literature DB >> 16435042

Vitiligo.

R H Huggins1, R A Schwartz, C Krysicka Janniger.   

Abstract

Vitiligo represents a selective destruction of the melanocytes. It is a relatively common, probably autoimmune disorder that affects people of all backgrounds and both genders. No particular group seems to be preferentially affected. Half of vitiligo patients have an onset before the age of 18 years. In regions where leprosy is endemic, individuals with vitiligo are often stigmatized due to similarities in appearance between the two diseases. We will review this important subject, emphasizing the latest therapeutic advances.

Entities:  

Mesh:

Year:  2005        PMID: 16435042

Source DB:  PubMed          Journal:  Acta Dermatovenerol Alp Pannonica Adriat        ISSN: 1318-4458


  10 in total

1.  Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.

Authors:  P Agretti; G De Marco; D Sansone; C Betterle; G Coco; A Dimida; E Ferrarini; A Pinchera; P Vitti; M Tonacchera
Journal:  J Endocrinol Invest       Date:  2010-03-22       Impact factor: 4.256

2.  Update on the genetics characterization of vitiligo.

Authors:  Hani A Al-Shobaili
Journal:  Int J Health Sci (Qassim)       Date:  2011-07

3.  Relationship of macrophage migration inhibitory factor levels in PBMCs, lesional skin and serum with disease severity and activity in vitiligo vulgaris.

Authors:  Lei Ma; Hai-Bo Xue; Xiu-Hao Guan; Chun-Mei Shu; Yu-Jie Zhang; Jun-Hua Zhang; Rong-Zhen An
Journal:  Braz J Med Biol Res       Date:  2013-05       Impact factor: 2.590

Review 4.  Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.

Authors:  Michael A Cardis; Cynthia Marie Carver DeKlotz
Journal:  Arch Dis Child       Date:  2017-03-28       Impact factor: 3.791

5.  Comparison of tyrosinase antibody, tyrosinase-related protein-1 and -2 antibodies, melanin-concentrating hormone receptor antibody levels with autologous serum skin test and autologous plasma skin test results in patients with vitiligo.

Authors:  Abdullah Unal; Hatice Uce Ozkol; Yasemin Bayram; Necmettin Akdeniz
Journal:  Postepy Dermatol Alergol       Date:  2020-02-25       Impact factor: 1.837

6.  Mechanisms of spatial and temporal development of autoimmune vitiligo in tyrosinase-specific TCR transgenic mice.

Authors:  Randal K Gregg; Lisa Nichols; Yiming Chen; Bao Lu; Victor H Engelhard
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

7.  Role of in vivo reflectance confocal microscopy in determining stability in vitiligo: a preliminary study.

Authors:  Wei Li; Suiquan Wang; Ai-E Xu
Journal:  Indian J Dermatol       Date:  2013-11       Impact factor: 1.494

8.  Whole Transcriptome Analysis (RNA Sequencing) of Peripheral Blood Mononuclear Cells of Vitiligo Patients.

Authors:  E Reimann; K Kingo; M Karelson; P Reemann; E Vasar; H Silm; S Kõks
Journal:  Dermatopathology (Basel)       Date:  2014-01-09

Review 9.  Current knowledge on psoriasis and autoimmune diseases.

Authors:  Nilmarie Ayala-Fontánez; David C Soler; Thomas S McCormick
Journal:  Psoriasis (Auckl)       Date:  2016-02-22

10.  Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo.

Authors:  Giovanny Aguilera-Durán; Antonio Romo-Mancillas
Journal:  Molecules       Date:  2020-09-25       Impact factor: 4.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.